Rare disease firm Amryt reveals a “major” gene therapy tie-up as revenues rise – City A.M.
City A.M. |
Rare disease firm Amryt reveals a "major" gene therapy tie-up as revenues rise
City A.M. Rare and orphan disease specialist Amryt Pharma has announced a major in-lincence agreement for a novel gene therapy platform as its revenues for 2017 jumped. In a trading update for the year to December 2017, Amryt said revenues had risen to €12.8m … Amryt Pharmaceuticals PLC licenses gene therapy platform from … Irish biopharma company and UCD to use gene therapy for rare skin disorder Amryt reports strong 2017 as revenues rise to almost €13m |
